Vivos Therapeutics (VVOS)10% owner bought ~$1.4M

~$1.4M

Approx. value · 1.04M sh @ $1.34

1.04M

Holds after · shares reported

Traded

Mar 31, 2026

Filed

Apr 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective as of February 4, 2026, the Board of Directors (the “ Board ”) of Vivos Therapeutics, Inc. (the “ Company ”), pursuant to the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Gregg C. E. Johnson as an independent director of the Board.”
2. Mar 31, 2026 · this disclosureInsider · Largest insider buy since 202010% owner purchased ~$1.4M of VVOS shares in the open market

What came next

1. Mar 31, 2026Insider · Largest insider buy since 202010% owner purchased ~$414K of VVOS shares in the open market
2. Apr 3, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
3. Apr 15, 2026Company filing · Form 8-K · ResultsReported its results
4. Apr 22, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule…”
5. Jun 8, 2026Company filing · Form 8-K · Material agreement, New debtReceived a notice from its stock exchange, and signed an important agreement (and 3 more items)“On June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “…”
6. Jun 15, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
7. Jun 25, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
8. Jul 7, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vivos Therapeutics

OQRO holds no insider, Congress, fund or contract record for Vivos Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VVOS page.

Other recent filings by Skaff Michael C, 10% owner

• SEC Form 4 at Vivos Therapeutics (VVOS)Apr 2, 2026

The full history of Skaff Michael C, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Vivos Therapeutics

• SEC Form 4Apr 2, 2026

Everything OQRO holds on this company is on its VVOS page.